Less Ads, More Data, More Tools Register for FREE

Pin to quick picksZotefoams Plc Regulatory News (ZTF)

Share Price Information for Zotefoams Plc (ZTF)

Share Price is delayed by 15 minutes
Get Live Data
433.00    0.00 (0.00%)
Bid:
0.00
Ask:
0.00
Spread: 2.50 (0.58%)
Market Cap: £212.96m
ZTF Live PriceLast checked at - London Stock Exchange

Intraday Zotefoams Plc Share Chart

Trading Update

15 Dec 2022 07:00

RNS Number : 7596J
Zotefoams PLC
15 December 2022
 

Zotefoams plc

("Zotefoams" or "Group" or "Company")

 

Trading Update

Continued positive momentum through Q4 and full year profit ahead of market expectations

 

15 December 2022 - Zotefoams, a world leader in cellular materials technology, today provides an update in respect of its financial year ending 31 December 2022.

As communicated in the Group's trading update of 13 October, performance over the nine months to 30 September 2022 had been strong, with revenues approximately 24% ahead of the comparable prior year period. 

Encouragingly, trading during October and November has remained strong, with both the Polyolefin Foams and High-Performance Products businesses continuing to deliver year-on-year growth as well as a continued focus on cost and efficiency. As a result, based on current FX rates, the Board now expects Group FY22 adjusted profit before income tax to be ahead of current market expectations*, with the extent of the outperformance primarily dependent on the timing of customer shipments in the final weeks of the year.

Cash generation also continues to be positive. The better than anticipated earnings performance should contribute to an appreciable reduction in leverage compared with that reported in the interims at 30 June 2022. 

Commenting on the update David Stirling, Group CEO of Zotefoams, said: 

"I am pleased that Zotefoams continues to perform well and deliver excellent growth in both revenue and profitability. Whilst this year has seen considerable challenges in the form of both cost and demand volatility, we have continued to demonstrate resilience in mitigating these, which is testament to Zotefoams' well-established products and experienced team.

"Whilst we expect a number of the challenges experienced this year to continue into 2023, we are confident in our ability to respond and we continue to see significant opportunity for the Group."

 

* Current Company-compiled consensus expectations for adjusted profit before income tax and separately disclosed items, for the year ending 31 December 2022, is £10.7m.

 

 

- Ends -

 

Enquiries:

 

Zotefoams plc

+44 (0) 208 664 1600

David Stirling, Group CEO

Gary McGrath, Group CFO

IFC Advisory

+44 (0) 203 934 6630

Graham Herring

Tim Metcalfe

Zach Cohen

 

About Zotefoams plc

Zotefoams plc (LSE - ZTF) is a world leader in cellular materials technology delivering optimal material solutions for the benefit of society. Utilising a variety of unique manufacturing processes, including environmentally friendly nitrogen expansion for lightweight AZOTE® polyolefin and ZOTEK® high-performance foams, Zotefoams sells to diverse markets worldwide. Zotefoams uses its own cellular materials to manufacture T-FIT® advanced insulation for demanding industrial markets. Zotefoams also owns and licenses patented microcellular foam technology to reduce plastic use in extrusion applications and for ReZorce® mono-material recyclable barrier packaging.

Zotefoams is headquartered in Croydon, UK, with additional manufacturing sites in Kentucky, USA and Brzeg, Poland (foam manufacture), Oklahoma, USA (foam products manufacture and conversion), Massachusetts, USA (MuCell Extrusion) and Jiangsu Province, China (T-FIT).

www.zotefoams.com

AZOTE®, ZOTEK®, ReZorce® and T-FIT® are registered trademarks of Zotefoams plc.

www.zotefoams.com

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTZZMMZRDKGZZM
Date   Source Headline
1st Jun 20174:30 pmRNSDirector/PDMR Shareholding
31st May 20177:00 amRNSDirector/PDMR Shareholding
17th May 20177:00 amRNSTrading Update
12th May 201711:16 amRNSDirector/PDMR Shareholding
12th Apr 20173:34 pmRNSAnnual Report and Accounts and Notice of 2017 AGM
12th Apr 20173:24 pmRNSDirector/PDMR Shareholding
12th Apr 20171:55 pmRNSHolding(s) in Company
10th Apr 20174:02 pmRNSDirector/PDMR Shareholding
6th Apr 20172:27 pmRNSHolding(s) in Company
6th Apr 20172:25 pmRNSHolding(s) in Company
28th Mar 201711:36 amRNSDirector/PDMR Shareholding
27th Mar 201710:16 amRNSHolding(s) in Company
24th Mar 20173:33 pmRNSHolding(s) in Company
23rd Mar 201710:11 amRNSHolding(s) in Company
22nd Mar 20173:28 pmRNSHolding(s) in Company
14th Mar 20175:28 pmRNSDirector/PDMR Shareholding
14th Mar 20177:00 amRNSFinal Results
9th Mar 20177:00 amRNSCoveris using MuCell® technology
15th Feb 201710:46 amRNSDirector/PDMR Shareholding
10th Feb 20177:00 amRNSHolding(s) in Company
1st Feb 20176:27 pmRNSHolding(s) in Company
12th Jan 20179:36 amRNSDirector/PDMR Shareholding
11th Jan 201710:33 amRNSHolding(s) in Company
10th Jan 20175:34 pmRNSHolding(s) in Company
9th Jan 20177:00 amRNSTrading Update
6th Jan 20177:00 amRNSAppointment of Joint Broker
6th Jan 20177:00 amRNSAcquires full ownership of its joint venture
22nd Dec 20164:35 pmRNSPrice Monitoring Extension
13th Dec 20161:58 pmRNSDirector/PDMR Shareholding
24th Nov 20167:00 amRNSHolding(s) in Company
15th Nov 201612:40 pmRNSDirector/PDMR Shareholding
14th Nov 201610:30 amRNSDirector Declaration
28th Oct 20167:00 amRNSThird Quarter Trading Update
25th Oct 20164:40 pmRNSSecond Price Monitoring Extn
25th Oct 20164:35 pmRNSPrice Monitoring Extension
24th Oct 201612:07 pmRNSSecond Price Monitoring Extn
24th Oct 201612:02 pmRNSPrice Monitoring Extension
20th Oct 20164:40 pmRNSSecond Price Monitoring Extn
20th Oct 20164:35 pmRNSPrice Monitoring Extension
19th Oct 20163:43 pmRNSHolding(s) in Company
18th Oct 201611:56 amRNSDirector/PDMR Shareholding
14th Oct 20164:35 pmRNSPrice Monitoring Extension
13th Oct 20164:35 pmRNSPrice Monitoring Extension
12th Oct 20165:56 pmRNSDirector/PDMR Shareholding
5th Oct 20164:29 pmRNSHolding(s) in Company
14th Sep 201611:16 amRNSDirector/PDMR Shareholding
23rd Aug 20164:40 pmRNSSecond Price Monitoring Extn
23rd Aug 20164:35 pmRNSPrice Monitoring Extension
12th Aug 20167:00 amRNSDirector/PDMR Shareholding
9th Aug 20167:00 amRNSTR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.